Liver cancer is the third most common malignant tumor in China, with about 110,000 deaths per year, accounting for 40% of deaths in the world. However, most of the liver cancer patients in China have a history of hepatitis and cirrhosis, and about 80% of them are already in the middle or late stage when they visit the clinic for various reasons and lose the opportunity of surgical treatment. Therefore, hepatic artery chemoembolization (TACE) has become the first choice for patients who cannot be treated surgically. However, the recurrence rate of TACE treatment is high and the long-term efficacy is not satisfactory. In recent years, with the great progress of modern radiotherapy technology, especially gyroscopic knife has obtained better efficacy than surgical resection in the treatment of liver cancer. Therefore, the use of modern radiotherapy technology for comprehensive treatment of liver cancer has become a research hotspot and development trend. Our center adopts hepatic artery embolization chemotherapy combined with gyroknife radiotherapy to treat advanced hepatocellular carcinoma with great efficacy. The liver is a typical radiation volume effect organ. High dose irradiation of liver tissue within a certain volume does not affect liver function too much, moreover, the unirradiated liver tissue has strong regenerative and functional compensatory ability, this feature provides an anatomical and functional basis for gyroknife treatment of liver tumors, therefore, gyroknife treatment of liver cancer is safe and effective. Gyroknife adopts the principle of γ-radiation multi-source rotational focusing so that the lesion is irradiated with high dose while the surrounding normal tissues are irradiated with low dose. At the same time, through CT positioning or CT/MRI image fusion and PET/CT positioning, the tumor of 3-5mm size as well as the volume ratio and position relationship between the tumor and the liver can be accurately determined. The local irradiation dose can be sufficient to kill the tumor cells without affecting the liver function within a certain volume range. For example, in gyroscopic radiotherapy for liver cancer, the fractionated dose is generally 3-15 Gy depending on the size, location and liver function of the tumor, therefore, if this fractionation mode is used for small liver cancer or liver metastases and liver function is relatively good, it can improve the local control rate without causing radiation damage. improve the local control rate. At present, the 5-year survival rate of surgical treatment of early stage I/II (diameter ≤2 cm, non-clinical symptoms and isolated) small hepatocellular carcinoma is about 53%, and the 1, 2 and 3-year survival rates of early stage I/II hepatocellular carcinoma treated with gyroscopic knife combined with TACE are 95%, and the survival rate of advanced stage III and above hepatocellular carcinoma is also improved to over 40%. With the advancement of modern radiotherapy technology, many small hepatocellular carcinomas that cannot be operated in early stage can be radically treated by modern radiotherapy with less damage to liver function. Therefore, gyroscopic knife combined with hepatic artery embolization has shown its absolute advantages in liver cancer treatment.